<div id="readability-page-1"><ul><li>3 Bargain Stocks Under $20 With Major Growth Potential</li></ul><p>Bioceres Crop Solutions Corp. (NASDAQ:BIOX - Free Report) - Investment analysts at Brookline Capital Management lowered their FY2026 earnings per share estimates for shares of Bioceres Crop Solutions in a research report issued on Tuesday, September 9th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of ($0.12) for the year, down from their previous estimate of $0.21. Brookline Capital Management currently has a &#34;Hold&#34; rating on the stock. The consensus estimate for Bioceres Crop Solutions' current full-year earnings is ($0.05) per share.</p><p>Several other equities analysts also recently issued reports on BIOX. Wall Street Zen raised shares of Bioceres Crop Solutions from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, August 31st. Canaccord Genuity Group  reaffirmed a &#34;hold&#34; rating and issued a $2.50 price objective (down previously from $6.50) on shares of Bioceres Crop Solutions in a report on Wednesday. Lake Street Capital reduced their target price on shares of Bioceres Crop Solutions from $8.00 to $5.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday. Finally, Oppenheimer  set a $5.00 target price on shares of Bioceres Crop Solutions in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $4.17.</p><p><b>Get Our Latest Report on BIOX</b></p><h2>Bioceres Crop Solutions Price Performance</h2><p>Shares of BIOX opened at $2.09 on Friday. Bioceres Crop Solutions has a 12 month low of $1.97 and a 12 month high of $8.93. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.02 and a quick ratio of 0.74. The stock has a fifty day moving average price of $3.32 and a 200 day moving average price of $4.10. The company has a market cap of $131.06 million, a P/E ratio of -2.58, a PEG ratio of 0.88 and a beta of 0.43. </p><h2>Institutional Investors Weigh In On Bioceres Crop Solutions</h2><p>Institutional investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp grew its position in  Bioceres Crop Solutions by 3,535.8% in the 1st quarter. Jones Financial Companies Lllp now owns 5,490 shares of the company's stock valued at $25,000 after buying an additional 5,339 shares in the last quarter.  Bank of America Corp DE raised its position in shares of  Bioceres Crop Solutions by 186.8% during the 4th quarter. Bank of America Corp DE now owns 5,735 shares of the company's stock worth $35,000 after buying an additional 3,735 shares in the last quarter.  Northern Trust Corp acquired a new stake in shares of  Bioceres Crop Solutions in the 4th quarter worth approximately $93,000.  Avanza Fonder AB bought a new position in shares of  Bioceres Crop Solutions in the first quarter valued at approximately $72,000.  Finally, PDT Partners LLC bought a new position in shares of  Bioceres Crop Solutions in the first quarter valued at approximately $81,000. Institutional investors and hedge funds own  17.68% of the company's stock. </p><h2>About Bioceres Crop Solutions</h2> (Get Free Report)<p>Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.</p><h2>Read More</h2><ul><li>Five stocks we like better than Bioceres Crop Solutions</li><li>How to Most Effectively Use the MarketBeat Earnings Screener</li><li>High-Flyers Near Resistance: 3 Stocks to Watch for a Dip</li><li>How to Invest in Blue Chip Stocks</li><li>Seagate Technology Leads S&amp;P 500: What’s Behind Its 120% Gain?</li><li>Stock Average Calculator      </li><li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklPWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklPWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bioceres Crop Solutions Right Now?</h2><p>Before you consider Bioceres Crop Solutions, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioceres Crop Solutions wasn't on the list.</p><p>While Bioceres Crop Solutions currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BIOX

<p>Investment analysts at Brookline Capital Management have reduced their FY2026 earnings per share estimate for Bioceres Crop Solutions Corp. (NASDAQ:BIOX) from $0.21 to ($0.12). The firm maintains a "Hold" rating on the stock. Other analysts have also adjusted their ratings, with Canaccord Genuity lowering its price target from $6.50 to $2.50, while Lake Street Capital set a target of $5.00. Currently, the stock has a consensus rating of "Moderate Buy" and a price target of $4.17.</p>

BIOX FY2026 EPS Reduced by Brookline Capital Management